Literature DB >> 1602305

The natural history of multiple sclerosis: a regional study with some longitudinal data.

D H Miller1, R W Hornabrook, G Purdie.   

Abstract

A regional survey of multiple sclerosis (MS) patients in Wellington, New Zealand in 1983 identified 245 patients, giving a prevalence (all categories included) of 72 per 100,000. Retrospective review of the history and medical records identified a poorer prognosis for disability where there was progressive onset of symptoms, secondary progression after a remitting phase, older age of onset (40 years or more), or a motor syndrome involving the limbs at presentation. In 1983 follow up data were obtained on 96 patients who were seen during a previous survey in 1968. For those with definite or probable MS, progression to severe disability (Kurtzke disability status scale (DSS) 6-9) or death (DSS 10) was seen in 26/34 with moderate disability (DSS 3-5) in 1968 and in only 5/29 with mild disability (DSS 0-2). When the analysis is confined to those with symptoms for at least five years in 1968, severe disability or death from MS occurred in 22/30 with moderate and 4/19 with mild disability (chi 2 = 10.8, p = 0.001). It is concluded that the patient's established disability level after five years of illness is a useful, but not infallible, prognostic indicator. From the follow up of the 1968 patients, the probability of MS-related mortality for a given disease duration was calculated. Using this survival distribution to adjust the disability ratings in the 1983 population, it was found that the proportion with mild disability decreased steadily with increasing disease duration, reaching 14% when the disease duration was more than 25 years.

Entities:  

Mesh:

Year:  1992        PMID: 1602305      PMCID: PMC489071          DOI: 10.1136/jnnp.55.5.341

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease.

Authors:  D MCALPINE
Journal:  Brain       Date:  1961-06       Impact factor: 13.501

2.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

3.  Survival in multiple sclerosis.

Authors:  S Poser; J F Kurtzke; W Poser; G Schlaf
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

4.  A clinical and laboratory study of benign multiple sclerosis.

Authors:  A J Thompson; M Hutchinson; J Brazil; C Feighery; E A Martin
Journal:  Q J Med       Date:  1986-01

5.  The prevalence of multiple sclerosis in New Zealand.

Authors:  R W Hornabrook
Journal:  Acta Neurol Scand       Date:  1971       Impact factor: 3.209

6.  Survival and death in multiple sclerosis.

Authors:  U Leibowitz; E Kahana; M Alter
Journal:  Brain       Date:  1969-03       Impact factor: 13.501

7.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

8.  Onset symptoms as predictors of mortality and disability in multiple sclerosis.

Authors:  B R Visscher; K S Liu; V A Clark; R Detels; R M Malmgren; J P Dudley
Journal:  Acta Neurol Scand       Date:  1984-11       Impact factor: 3.209

9.  Studies on the natural history of multiple sclerosis--8. Early prognostic features of the later course of the illness.

Authors:  J F Kurtzke; G W Beebe; B Nagler; L T Kurland; T L Auth
Journal:  J Chronic Dis       Date:  1977-12

Review 10.  The natural history of multiple sclerosis.

Authors:  B G Weinshenker; G C Ebers
Journal:  Can J Neurol Sci       Date:  1987-08       Impact factor: 2.104

View more
  10 in total

Review 1.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

2.  Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.

Authors:  M Trojano; C Avolio; C Manzari; A Calò; F De Robertis; G Serio; P Livrea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

3.  Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis.

Authors:  Katrin Weier; Andreas Beck; Stefano Magon; Michael Amann; Yvonne Naegelin; Iris K Penner; Markus Thürling; Volker Aurich; Tobias Derfuss; Ernst-Wilhelm Radue; Christoph Stippich; Ludwig Kappos; Dagmar Timmann; Till Sprenger
Journal:  J Neurol       Date:  2012-06-19       Impact factor: 4.849

4.  The role of the cerebellum in multiple sclerosis.

Authors:  Katrin Weier; Brenda Banwell; Antonio Cerasa; D Louis Collins; Anne-Marie Dogonowski; Hans Lassmann; Aldo Quattrone; Mohammad A Sahraian; Hartwig R Siebner; Till Sprenger
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

5.  Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity.

Authors:  D Kidd; A J Thompson; B E Kendall; D H Miller; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 6.  Predicting responders to therapies for multiple sclerosis.

Authors:  Jordi Río; Manuel Comabella; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2009-10       Impact factor: 42.937

7.  Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration.

Authors:  Lynn van Olst; Carla Rodriguez-Mogeda; Carmen Picon; Svenja Kiljan; Rachel E James; Alwin Kamermans; Susanne M A van der Pol; Lydian Knoop; Iliana Michailidou; Evelien Drost; Marc Franssen; Geert J Schenk; Jeroen J G Geurts; Sandra Amor; Nicholas D Mazarakis; Jack van Horssen; Helga E de Vries; Richard Reynolds; Maarten E Witte
Journal:  Acta Neuropathol       Date:  2021-03-29       Impact factor: 17.088

8.  Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients.

Authors:  Katrin Parmar; Vladimir S Fonov; Yvonne Naegelin; Michael Amann; Jens Wuerfel; D Louis Collins; Laura Gaetano; Stefano Magon; Till Sprenger; Ludwig Kappos; Cristina Granziera; Charidimos Tsagkas
Journal:  Cerebellum       Date:  2021-08-21       Impact factor: 3.648

9.  Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.

Authors:  Cecilia Smith Simonsen; Heidi Øyen Flemmen; Line Broch; Cathrine Brunborg; Pål Berg-Hansen; Stine Marit Moen; Elisabeth Gulowsen Celius
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

10.  Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.

Authors:  Katrin Weier; Iris K Penner; Stefano Magon; Michael Amann; Yvonne Naegelin; Michaela Andelova; Tobias Derfuss; Christoph Stippich; Ernst-Wilhelm Radue; Ludwig Kappos; Till Sprenger
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.